156 related articles for article (PubMed ID: 36165395)
1. A bivalent aptamer and terminus-free siRNA junction nanostructure for targeted gene silencing in cancer cells.
Yang F; Li S; Yuan R; Xiang Y
J Mater Chem B; 2022 Oct; 10(40):8315-8321. PubMed ID: 36165395
[TBL] [Abstract][Full Text] [Related]
2. Self-Assembled DNA Nanostructure as a Carrier for Targeted siRNA Delivery in Glioma Cells.
Zhou Y; Yang Q; Wang F; Zhou Z; Xu J; Cheng S; Cheng Y
Int J Nanomedicine; 2021; 16():1805-1817. PubMed ID: 33692623
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer.
Dhanya CR; Mary AS; Madhavan M
Chem Biol Drug Des; 2023 May; 101(5):1162-1180. PubMed ID: 36099164
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
5. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S
Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566
[TBL] [Abstract][Full Text] [Related]
6. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
Hong CA; Nam YS
Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
[TBL] [Abstract][Full Text] [Related]
7. Targeted Delivery of Rab26 siRNA with Precisely Tailored DNA Prism for Lung Cancer Therapy.
Liu Q; Wang D; Xu Z; Huang C; Zhang C; He B; Mao C; Wang G; Qian H
Chembiochem; 2019 May; 20(9):1139-1144. PubMed ID: 30610755
[TBL] [Abstract][Full Text] [Related]
8. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
9. Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.
Zhou J; Rossi JJ; Shum KT
Methods Mol Biol; 2015; 1297():169-85. PubMed ID: 25896003
[TBL] [Abstract][Full Text] [Related]
10. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
[TBL] [Abstract][Full Text] [Related]
11. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
[TBL] [Abstract][Full Text] [Related]
12. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
13. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
14. A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo.
Taghdisi SM; Danesh NM; Ramezani M; Yazdian-Robati R; Abnous K
Mol Pharm; 2018 May; 15(5):1972-1978. PubMed ID: 29669200
[TBL] [Abstract][Full Text] [Related]
15. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
Zhou J; Li H; Li S; Zaia J; Rossi JJ
Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
[TBL] [Abstract][Full Text] [Related]
16. Tetrahedral Framework Nucleic Acids Loaded with Aptamer AS1411 for siRNA Delivery and Gene Silencing in Malignant Melanoma.
Xiao D; Li Y; Tian T; Zhang T; Shi S; Lu B; Gao Y; Qin X; Zhang M; Wei W; Lin Y
ACS Appl Mater Interfaces; 2021 Feb; 13(5):6109-6118. PubMed ID: 33497198
[TBL] [Abstract][Full Text] [Related]
17. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
Bagalkot V; Gao X
ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
[TBL] [Abstract][Full Text] [Related]
18. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system.
Wei J; Song R; Sabbagh A; Marisetty A; Shukla N; Fang D; Najem H; Ott M; Long J; Zhai L; Lesniak MS; James CD; Platanias L; Curran M; Heimberger AB
Oncoimmunology; 2022; 11(1):2062827. PubMed ID: 35433114
[TBL] [Abstract][Full Text] [Related]
19. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
[TBL] [Abstract][Full Text] [Related]
20. Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.
Catuogno S; Esposito CL; Giangrande PH
Methods Mol Biol; 2021; 2282():31-42. PubMed ID: 33928568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
